Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel , Aug. 31, 2015 ... Dario™ Diabetes Management Solution, today announced it recently ... million. Funds will be used to support the ... the Dario, a mobile, cloud-based, diabetes management solution ... stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, and ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
(Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
(Date:8/28/2015)... ... 2015 , ... Riordan-McKenna Institute founders, stem cell ... the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies ... knee wound. , The case involved a 78-year-old male, who presented with a ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced ... ended September 30, 2007. Net,revenues totaled $7,373,770 for the ... period in 2006. Gross profit decreased by 2.66% due ... sales from Aida,s,transfusion and injection forms of etimicin sulfate ...
... Million Financing, WOBURN, Mass., Nov. 15 BioVex ... the treatment and,prevention of cancer and infectious disease, announced ... the completion of a,venture debt transaction, raising a total ... the capital to complete its preparations for, and,to commence, ...
Cached Biology Technology:Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4BioVex Closes Second Round of Series E Financing 2
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... , June 4, 2013  With invasions of computer systems ... Identify Security Software Inc. ( www.identifyss.com ) today announced ... http://photos.prnewswire.com/prnh/20130604/FL25436LOGO ) "Identify Security Software ... way for businesses and institutions to manage and control ...
... and NEW ORLEANS , June 3, 2013 ... Microsoft demonstrates an FPC fingerprint touch sensor in combination with a ... demonstrations showcase a number of innovative online use cases using FPC,s ... to sign on to their Microsoft account, make online payments and ...
... the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has ... protein linked to stem cell-like behavior in terminal-stage chronic ... that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , is ...
Cached Biology News:Identify Security Software to Make Cyberspace Secure 'Once And For All' 2Identify Security Software to Make Cyberspace Secure 'Once And For All' 3Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1 2Singapore research team identifies new drug target in deadly form of leukemia 2
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Evolutionarily conserved signaling intermediate in Toll pathway...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: